Skip Navigation
moon
sailing-ship
boy

YiPSCELL is a biotechnology company developing regenerative cell therapies based on induced pluripotent stem cell (iPSC) technology. Led by MIUChon™, our osteoarthritis therapy candidate, we develop iPSC-based therapies and provide clinical-grade iPSC line manufacturing and distribution as well as GMP-based contract development and manufacturing (CDMO) services. We pursue the 3Rs: Recovery, Regeneration and Rejuvenation.

Tour YiPSCELL

Take a drone tour of YiPSCELL’s laboratories and GMP facility.

CEO Message

YiPSCELL’s executives and employees consider “Seek for the Sick”, the company’s core philosophy, as the most important value.

Greetings!
I'm JiHyeon Ju, CEO of YiPSCELL

YiPSCELL is a biotech company that uses induced pluripotent stem cells to produce normal and diseased cell lines, provide platform services for disease modeling, and develop stem cell-based therapeutics.

“Seek for the sick” We are committed to research, development, and application processes to diagnose and treat patients with incurable diseases that cannot be resolved with modern medicine.

“From Therapy to Recovery” We have established a strategy to focus on induced pluripotent stem cells among various stem cells. Induced pluripotent stem cells have great potential because it is easy to acquired cells and has a wide range of differentiation capabilities. We will develop stem cell therapies that aim regeneration and functional recovery of ageing organs so as to provide promising treatments in this era of ultra-aging society.

“Without passion, nothing is gained” The process of developing new treatments requires continuous eagerness and enthusiasm. With this passion, YiPSCELL aims to contribute to the society by conducting R&D on induced pluripotent stem cells from therapeutic approaches for patients with incurable disease. We would be grateful if you would follow us with great interest.

CEO JiHyeon Ju
YiPSCELL Inc.

Business

  • 1

    iPSC cell therapy — MIUChon™

    We are developing MIUChon™, an injectable 3D chondrogenic micropellet therapy for osteoarthritis made from clinical-grade iPSCs. Following Korea’s first clinical administration of an iPSC-based cell therapy (Apr 2025), dosing was completed in a 30-patient randomized controlled study (Oct 2026).

  • 2

    iPSC banking & distribution

    We manufacture, bank and distribute research-grade and clinical-grade iPSC lines, as well as patient-derived disease lines such as Alzheimer's disease lines. We are also developing hypoimmunogenic universal iPSC lines.

  • 3

    GMP CDMO

    We provide contract development and manufacturing of cell therapies in our 614.74㎡ GMP facility with 60 rooms, completed in August 2022. We hold licenses as a cell processing facility (2023), an advanced biopharmaceutical manufacturer (Sep 2023) and a human cell management business (Aug 2024).

  • 4

    Organoid-based alternatives to animal testing

    We evaluate drug efficacy and toxicity using iPSC-derived cells and organoids.

  • 5

    Cosmetic ingredients

    We are developing iPSC-derived exosome and secretome ingredients for cosmetics.

History

YiPSCELL conducts clinical immunology & stem cell research and aims to proceed induced pluripotent stem cell research and develop therapeutics based on our research.

2026

  • 11

    Selected for the 2026 Top 50 SME R&D Achievements (strategic technology) and awarded a commendation from the Minister of SMEs and Startups

  • 10

    MIUChon results presented at the ISSCR international symposium marking 20 years of iPSCs (Kyoto, Japan)

  • 10

    Korean patent granted for hypoimmunogenic universal iPSCs

  • 10

    iPSC-derived chondrocyte therapy MIUChon: dosing completed in the 30-patient randomized controlled study

  • 08

    Kick-off exchange meeting of the advanced-bio self-driving lab (SDL) project as its demonstration hub (KRW 8.25 billion, six institutions)

  • 08

    One-year MIUChon results presented at the KSSCR annual meeting (serial MRI showed reduced defects and recovering cartilage thickness)

  • 07

    Presented the global iPSC Cell Hub strategy at BIOCHINA Global Forum @ Korea 2026

  • 07

    iPSC-derived chondrocyte therapy MIUChon: 12-month follow-up completed in the first 3 patients, establishing one-year safety with no serious treatment-related adverse events

  • 06

    Clinical-grade iPSC lines delivered to Celloid and Ethicstem

  • 04

    Joined the Ministry of Science and ICT's universal self-driving lab (K-cell SDL) project as a co-research institution

  • 01

    Invited talk at Keystone Symposia (Kyoto, Japan) on MIUChon clinical research

  • 01

    Built 30 Alzheimer’s patient-derived iPSC lines with Ajou University Medical Center and signed a distribution agreement (launch of iCellHub-NeuroAD-RUO™)

2025

  • 12

    Clinical-grade manufacturing and cartilage-regeneration mechanism of MIUChon published in Science Advances

  • 11

    MIUChon 30-patient randomized, double-blind, placebo-controlled study approved by the Korean review committee for advanced regenerative medicine

  • 10

    Presented at BIO JAPAN 2025 as a representative Korean company

  • 09

    Contract with Ono Pharmaceutical (Japan) for iPSC-based drug efficacy evaluation services

  • 07

    Commendation from the Minister of Science and ICT as an outstanding corporate research institute

  • 07

    Clinical-grade iPSC distribution agreements worth KRW 6 billion in total with Asan Medical Center, Ethicstem and Celloid

  • 07

    MIUChon: dosing completed in all 3 patients of the pilot clinical study

  • 05

    Selected as the first research partner of Thermo Fisher Scientific’s CGT Vision Center; research collaboration on a closed, automated manufacturing platform for iPSC therapies

  • 04

    First patient dosed with MIUChon

2024

  • 12

    Signed a CDMO contract with Asan Medical Center for development of a corneal endothelial cell therapy

  • 10

    Signed a CDMO contract for exosome development

  • 09

    Established a branch office in Japan

  • 08

    Winner of the “IR52 Jang Young-Sil Award” for technological innovation

  • 08

    Acquisition of MFDS “Human Cell Management Business” license

  • 08

    MIUChon clinical research approved under the Advanced Regenerative Medicine Act

2023

  • 12

    recipient the 2023 Presidential Award for Entrepreneurship in Biohealthcare

  • 11

    recipient the 2023 Minister of Trade, Industry and Energy's Recognition for Job Creation Award

  • 09

    Obtained a manufacturing license for advanced biopharmaceuticals

  • 09

    Signed MOU with 'Acrocell Biosciences'

  • 08

    Signed MOU with 'Surginex'

  • 07

    Signed MOU with 'One Heart Blood Center'

  • 05

    Signed MOU with ‘AJOU University Institute of Advanced Medical Studies’

  • 05

    Signed MOU with 'Daewoong Pharmaceutical '

  • 05

    Selected as one of the “Small Business Administration Super Gap Startups 1000+”

  • 04

    Selected as a follow-up support project for BIG3 Startup Package (fostering new industry startups)

  • 04

    Selected for the Health Industry Technology Valuation Project

  • 04

    Acquisition of GMP cell processing facility license

  • 03

    Personalized iPSC Bank Start

  • 02

    Korea's first CAR-T therapy approved for systemic lupus erythematosus patients in South Korea

  • 01

    Signed MOU with 'EDGENE'

2022

  • 12

    Apply for MIUChon Patent

  • 12

    Signed MOU with 'curocell'

  • 12

    Signed MOU with 'Paean Biotechnology'

  • 12

    Raised 3 billion won in bridge funding

  • 11

    Signed MOU with 'ToolGen Bio'

  • 11

    Winner of the Ministerial Award for Technology Commercialization Achievement from the Ministry of Health and Welfare

  • 11

    Raised 10 billion won in bridge funding

  • 11

    Selected as an outstanding company for technological innovation based on industry-academia cooperation

  • 09

    Selected as a recipient of the 2022 Technology Protection Leading Company Development Project

  • 06

    Extended Moving to 'Omnibus Park'

  • 01

    Selected as a National 1000 Innovative Company by the Ministry of SMEs and Startups

  • 01

    Apply for a Cell Processing Facility (GMP) License

  • 01

    Signed a license agreement with CiRA in Japan

  • 01

    Signed MOU with 'MDimune'

2021

  • 12

    Awarded “Excellence in LMO Security Management for Pilot Research Facilities” by the Minister of Science, ICT and Future Planning 2021

  • 09

    Signed MOU with 'Jasang Bio'

  • 07

    Production of clinical grade induced pluripotent stem cell lines

  • 06

    Certification as Venture (Start-up) Company

  • 05

    Investments Worth 12 Billion Korean Won Secured in Series A Round (INTERVEST, AJU IB, PremierPartners, HB INVESTMENT)

  • 02

    YiPSCELL Laboratory Receives LMO Certification

2020

  • 11

    3rd Floor GCLP-Level Laboratory Opens

  • 11

    Won “Minister Citation of Ministry of Gender Equality and Family” at K-Startup Challenge 2020

  • 09

    Investment promotion (Daewoong Pharmaceutical Co, Ltd)

  • 09

    Commercialization support project of Innovation Growth (Seoul Business Agency)

  • 09

    Commercialization support project of BIG 3 R&D (Ministry of SMEs and Startups)

  • 05

    Start-up leap forward package support project (KISED)

  • 05

    Commercialization support project of BIG 3 innovation field start-up package (KIAT)

  • 04

    Headquarter expansion and relocation (47-3 Banpo-daero 39-gil, Seocho-gu, Seoul)

2019

  • 12

    Patent transfer contract and technology transfer between The Catholic University Industry-Academic Cooperation Foundation and CiSTEM

  • 11

    Catholic Master Cell, the first clinical trial for osteoarthritis patients

  • 10

    Won “Best Award” at 2019 Anti-Aging Health Startup Fair hosted by Korea Economic Daily

  • 10

    Awarded for contributing to commercialization of health and medical technology Awarded by KHIDI

  • 09

    Initial start-up package business order

  • 05

    Signed a joint development contract with T&R Biofab and CiSTEM for treatment of rare immune diseases

  • 03

    Innovative startup member business of KHIDI

2018

  • 12

    Patent for systemic sclerosis disease model and its use (application number 10-2019-0177114, PCT/KR2019/018654)

  • 06

    Patent on a method for producing a pellet of chondrocytes from human induced pluripotent stem cells and its use (application number 10-2018-0072875)

  • 01

    Patent registration of chondrocytes induced differentiation using separation by cell size through centrifugation (Registration No. 10-2014020)

2017

  • 12

    Patent for a method of manufacturing a composition for differentiation of chondrocytes using human pluripotent cells derived from umbilical cord blood mononuclear cells of HLA homozygous
    (Registration No.: 10-2030906)

  • 02

    Founded CiSTEM Co., Ltd. located in Catholic University, 222 Banpo-daero, Seocho-gu, Seoul

2016

  • 03

    Catholic iPSC Research Center (CiRC) Established Induced Pluripotent Stem Cell Application Research Center under the Catholic University of Korea

2010

  • 03

    Established CiSTEM laboratory

Brand Story

YiPSCELL’s visual identity was inspired by three things.

  • The Rod of Asclepius God of medicine, to express YiPSCELL’s ideology devoted to human health
  • Helix structure of a DNA to symbolize YiPSCELL’s efforts to because the leading company in the field of biology science
  • As we prepare a signpost to indicate the future of YiPSCELL for development and delve into unlimited and infinite

The completed identity as whole resembles an alive branch that represents blessing and creates an association with the company name similarly to the Korean “leaf”. Each quadrilateral that makes up the identity symbolizes core values that YiPSCELL pursues : Compassion, Supremacy, and Contribution.

Recruit

  • DREAM

    Dreaming like a boy

  • CHALLENGE

    Challenging the distant seas together dauntlessly

  • VISION

    “YiPSCELL’s People” shining like a star

Send a Job Application

If you want to join the company, please send the application form to the email above.

Contact Us

Company Name
YiPSCELL Inc.
CEO
JiHyeon Ju
Business registration number
651-87-00610

Address
L2, Omnibus Park, Banpo-dearo 222, Seocho-gu, Seoul, Korea
Tel
+82 (2) 1522 3325
Fax
+82 (2) 2210 1018
E-mail
support@yipscell.com
Operation hour
Open 9:00AM ~ 6:00PM (Lunch break 12PM ~ 1PM)
Close Sat · Sun · Holidays
moon
sailing-ship
boy